At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 482 enrolled
Drug / intervention
Lithium +1 moredrug
Likely dose
Lithium 900mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer And a Classic Mood Stabilizer for Bipolar Disorder
In Brief
A Phase 4 clinical trial evaluating Lithium and Quetiapine for Bipolar Disorder. Completed, enrolled 482 participants across 11 sites.
Detailed Summary
The purpose of this study is to compare the effectiveness of lithium and quetiapine for the treatment of individuals with bipolar disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder
CountriesUnited States
CollaboratorsAgency for Healthcare Research and Quality (AHRQ)
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedApr 2011
Primary CompletionApr 2013
Study CompletionSep 2013
TodayJul 2026
First PostedApr 8, 2011
Enrollment StartSep 1, 2010
Primary CompletionApr 1, 2013
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.2 years ago
Interventions
Lithiumdrug
600-900mg per day over 6 months
Quetiapinedrug
100-800mg a day over 6 months